Brand Name(s):Adenuric

Indication:Gout prophylaxis



Review Date:Aug-24

Drug Safety Update
Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
There have been rare but serious reports of hypersensitivity reactions, including Stevens-Johnson syndrome and acute anaphylactic shock, with febuxostat (Adenuric). Febuxostat must be stopped immediately if hypersensitivity occurs, and must not be re-started in patients who have ever developed a hypersensitivity reaction to febuxostat.
MHRA June 2012

Febuxostat is suitable for prescribing in primary care in patients who are intolerant of allopurinol or for whom allopurinol is contraindicated, in line with NICE guidance.

Febuxostat (Adenuric) for the treatment of chronic hyperuricaemia in gout patients
MTRAC Verdict & Summary March 2010

Febuxostat, within its marketing authorisation, is recommended as an option for the management of chronic hyperuricaemia in gout only for people who are intolerant of allopurinol or for whom allopurinol is contraindicated.

People currently receiving febuxostat should have the option to continue therapy until they and their clinicians consider it appropriate to stop.

Febuxostat for the management of hyperuricaemia in people with gout DEC 2008